COMP <GO>
CMMB vs INM // REVENUE GROWTH (YOY)
Chemomab Therapeutics Ltd. (NASDAQ) VS. InMed Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: CMMB 0
— INM 3
■ METRIC PARITY
LAST: $1.09 (-0.91%) • MKT CAP: $8.8M
revenue-growth
—
LAST: $1.63 (+1.61%) • MKT CAP: $8.9M
revenue-growth
7.50%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CMMB VS. INM)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CMMB | INM | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 34.50% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | — | 7.50% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 4/9 | -2.00 | INM | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 33.5 | 71.8 | -38.30 | INM | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $8.8M | $8.9M | -$154.3K | INM | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CMMB REV | INM REV | CMMB GROSS % | INM GROSS % | CMMB FCF | INM FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $4.9M | — | 34.5% | -$11.1M | -$8.1M |
| FY 2024 | $0 | $4.6M | — | 23.9% | -$15.4M | -$7.0M |
| FY 2023 | $0 | $4.1M | — | — | -$23.6M | -$7.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CMMB // BETA —
INM // BETA —